Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBT Margin: 2023-2025

Historic EBT Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to 1,108.33%.

  • Inhibrx Biosciences' EBT Margin was N/A to 1,108.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 1,740.37%, marking a year-over-year change of. This contributed to the annual value of 843,787.00% for FY2024, which is 85710500.00% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported EBT Margin of 1,108.33% as of Q3 2025, which was up 21.50% from 912.19% recorded in Q2 2025.
  • Inhibrx Biosciences' EBT Margin's 5-year high stood at 1,610.67% during Q1 2025, with a 5-year trough of -287,741.18% in Q2 2023.
  • Its 3-year average for EBT Margin is -46,090.23%, with a median of -5,628.76% in 2023.
  • Within the past 5 years, the most significant YoY rise in Inhibrx Biosciences' EBT Margin was 25,308,322bps (2024), while the steepest drop was 4,223,624bps (2024).
  • Inhibrx Biosciences' EBT Margin (Quarterly) stood at -5,628.76% in 2023, then plummeted by 4,223,624bps to -47,865.00% in 2024, then skyrocketed by 3,557,015bps to 1,108.33% in 2025.
  • Its EBT Margin stands at 1,108.33% for Q3 2025, versus 912.19% for Q2 2025 and 1,610.67% for Q1 2025.